Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09257-5
Abstract: Alemtuzumab (ATZ) is an established highly effective treatment in relapsing-remitting multiple sclerosis (RRMS) [1–3]. Secondary autoimmune disorders in MS patients treated with alemtuzumab have been reported in a frequency of about 40% for thyroid disorders,… read more here.
Keywords: secondary autoimmune; treatment; autoimmune disease; alemtuzumab ... See more keywords
Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09272-6
Abstract: BackgroundNo postmarketing randomised clinical trials are available about alemtuzumab, and real-world data are limited. We aimed to analyse the efficacy and safety of alemtuzumab in a single-centre cohort of patients with relapsing–remitting MS.MethodsPatients who took… read more here.
Keywords: alemtuzumab real; efficacy safety; cohort patients; safety alemtuzumab ... See more keywords
Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing–remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09288-y
Abstract: Alemtuzumab, a monoclonal antibody against CD52, is a highly effective treatment of relapsing–remitting multiple sclerosis (RRMS), but it is known to cause secondary autoimmunity in 40% of patients [1]. We present a case of a… read more here.
Keywords: relapsing remitting; treatment; treatment relapsing; alemtuzumab ... See more keywords
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
Sign Up to like & getrecommendations! Published in 2017 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2017.09.028
Abstract: BACKGROUND Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be depleted by alemtuzumab, thereby potentially contributing… read more here.
Keywords: alemtuzumab treatment; treatment; year; alemtuzumab ... See more keywords
Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
Sign Up to like & getrecommendations! Published in 2018 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2017.12.009
Abstract: The anti-CD52 monoclonal antibody alemtuzumab is a highly active treatment for multiple sclerosis (MS) causing rapid depletion of B and T lymphocytes with nadir one month after last infusion. Opportunistic Cytomegalovirus (CMV) infections have been… read more here.
Keywords: cmv reactivation; treatment; alemtuzumab; multiple sclerosis ... See more keywords
Development and Validation of an Efficient and Highly Sensitive Enzyme-Linked Immunosorbent Assay for Alemtuzumab Quantification in Human Serum and Plasma
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000001037
Abstract: Supplemental Digital Content is Available in the Text. Background: Alemtuzumab is a humanized monoclonal antibody that targets the CD52 glycoprotein expressed on most lymphocytes, subsequently inducing complement-mediated and antibody-mediated cytotoxicity. Owing to its ability to… read more here.
Keywords: enzyme linked; validation; linked immunosorbent; alemtuzumab ... See more keywords
Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006440
Abstract: Key Points • Treatment with IL-15 before alemtuzumab was safe and led to decreased number and proliferative activity of T-cell leukemic cells.• IL-15 was associated with increased activation and proliferation of patient-derived NK and CD8+… read more here.
Keywords: cell; mediated adcc; augments cell; interleukin augments ... See more keywords